Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?
- 1 November 2010
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 24 (Suppl 5), S15-S18
- https://doi.org/10.1097/01.aids.0000391011.40892.ff
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan AfricaAIDS, 2008
- Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutáneaEnfermedades Infecciosas y Microbiología Clínica, 2003
- No Effect of Isoniazid Prophylaxis for Purified Protein Derivative–Negative HIV-Infected Adults Living in a Country With Endemic Tuberculosis: Results of a Randomized TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1997
- A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for TuberculosisNew England Journal of Medicine, 1997
- Isoniazid preventive therapy for tuberculosis in HIV-1-infected adultsAIDS, 1997
- Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'IvoireThe Lancet, 1995
- The mortality and pathology of HIV infection in a West African cityAIDS, 1993
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993